Home » Allergan, Sanwa Kagaku Kenkyusho Sign Exclusive Licensing Agreement
Allergan, Sanwa Kagaku Kenkyusho Sign Exclusive Licensing Agreement
March 28, 2005
Allergan has entered into an exclusive licensing agreement with Sanwa Kagaku Kenkyusho (Sanwa) to develop and commercialize POSURDEX for the ophthalmic specialty market in Japan. POSURDEX is an investigational, bioerodable, extended release implant that delivers dexamethasone to the targeted disease site at the back of the eye for the treatment of macular edema. The companies currently estimate Japan's annual macular edema market could be over $100 million.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct